Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.
Things are heating up in the race for a respiratory syncytial virus (RSV) vaccine.Novavax reported Phase II results for its investigational vaccine just a week ago, and now, Danish biotech Bavarian Nordic is starting a Phase I trial of its candidate.
Kerrisdale Capital is maintaining the pressure on Bavarian Nordic. Having precipitated a 13% drop in the stock of Bavarian Nordic in the 10 days since it unveiled its short thesis, the hedge fund is now holding a follow-up call to expand on its theory that the Danish drugmaker is a busted flush.
As it works to bring its prostate cancer vaccine Prostvac to market and expand its smallpox vaccine business, Danish vaccine maker Bavarian Nordic this week encountered a new set of challenges. It's the target of a short-selling campaign.
Hedge fund Kerrisdale Capital has orchestrated an attack on Bavarian Nordic, the centerpiece of which is a 52-page report that argues the valuation of the Danish drugmaker is based on misplaced faith in the likelihood of its cancer vaccine succeeding in Phase III.
Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.
Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.
On Tuesday, the U.S. government placed a large new order for Bavarian Nordic's smallpox vaccine while the company continues work to improve its formulation to offer more stockpiling flexibility.
Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some of its luster over the past year through deals with Bristol-Myers Squibb and Johnson & Johnson, but has no desire to cash in on its moment in the limelight.
Despite the M&A wave across biopharma that doesn't show signs of slowing, Bavarian Nordic's top dog has said his company isn't interested in getting involved.